210 related articles for article (PubMed ID: 30846172)
1. Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual.
Wang YQ; Lv JW; Tang LL; Du XJ; Chen L; Li WF; Liu X; Guo Y; Lin AH; Mao YP; Sun Y; Chen YP; Ma J
Oral Oncol; 2019 Mar; 90():23-29. PubMed ID: 30846172
[TBL] [Abstract][Full Text] [Related]
2. Impact of prior cancer on the overall survival of patients with nasopharyngeal carcinoma.
Wang X; Wang Z; Chen Y; Lin Q; Chen H; Lin Y; Lu L; Zheng P; Chen X
Am J Otolaryngol; 2022; 43(1):103235. PubMed ID: 34563802
[TBL] [Abstract][Full Text] [Related]
3. Histological subtype remains a prognostic factor for survival in nasopharyngeal carcinoma patients.
Pan XX; Liu YJ; Yang W; Chen YF; Tang WB; Li CR
Laryngoscope; 2020 Mar; 130(3):E83-E88. PubMed ID: 31188486
[TBL] [Abstract][Full Text] [Related]
4. Impact of prior cancer on outcomes in nasopharyngeal carcinoma.
Zhou H; Zhang Y; Liu J; Fang W; Yang Y; Hong S; Chen G; Zhao S; Shen J; Xian W; Zhang Z; Chen X; Zhao H; Huang Y; Zhang L
Ann Transl Med; 2019 Jul; 7(14):299. PubMed ID: 31475169
[TBL] [Abstract][Full Text] [Related]
5. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.
Laccetti AL; Pruitt SL; Xuan L; Halm EA; Gerber DE
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25667420
[TBL] [Abstract][Full Text] [Related]
6. Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria.
Sun X; Li L; Xu L; Zhou Z; Chen J; Wang J; Zhang Y; Hu D; Chen M
BMC Cancer; 2021 Feb; 21(1):147. PubMed ID: 33563246
[TBL] [Abstract][Full Text] [Related]
7. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
[TBL] [Abstract][Full Text] [Related]
8. Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer.
Pruitt SL; Laccetti AL; Xuan L; Halm EA; Gerber DE
Br J Cancer; 2017 Mar; 116(6):717-725. PubMed ID: 28196065
[TBL] [Abstract][Full Text] [Related]
9. Benefits of local tumor excision and pharyngectomy on the survival of nasopharyngeal carcinoma patients: a retrospective observational study based on SEER database.
Sun J; Huang Z; Hu Z; Sun R
J Transl Med; 2017 May; 15(1):116. PubMed ID: 28558725
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment age and serum lactate dehydrogenase as predictors of synchronous second primary cancer in patients with nasopharyngeal carcinoma.
Yeh CF; Ho CY; Chin YC; Shu CH; Chao YT; Lan MY
Oral Oncol; 2020 Nov; 110():104990. PubMed ID: 32932171
[TBL] [Abstract][Full Text] [Related]
11. Impact of prior cancer on eligibility for lung cancer clinical trials.
Gerber DE; Laccetti AL; Xuan L; Halm EA; Pruitt SL
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25253615
[TBL] [Abstract][Full Text] [Related]
12. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
13. A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry.
Lv JW; Huang XD; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Lin AH; Ma J; Sun Y
Cancer Res Treat; 2018 Apr; 50(2):324-334. PubMed ID: 28421724
[TBL] [Abstract][Full Text] [Related]
14. The Five-Year Survival Rate of Patients with Nasopharyngeal Carcinoma Based on Tumor Response after Receiving Neoadjuvant Chemotherapy, Followed by Chemoradiation, in Indonesia: A Retrospective Study.
Dwijayanti F; Prabawa A; Besral ; Herawati C
Oncology; 2020; 98(3):154-160. PubMed ID: 31995803
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
[TBL] [Abstract][Full Text] [Related]
16. Impact of prior cancer history on survival of patients with gastric cancer.
Wen L; Yu K; Lu H; Zhong G
Eur J Surg Oncol; 2021 Sep; 47(9):2286-2294. PubMed ID: 33632589
[TBL] [Abstract][Full Text] [Related]
17. Impact of age on survival of locoregional nasopharyngeal carcinoma: An analysis of the Surveillance, Epidemiology, and End Results program database, 2004-2013.
Huang SJ; Tang YY; Liu HM; Tan GX; Wang X; Zhang H; Yang F; Yang S
Clin Otolaryngol; 2018 Oct; 43(5):1209-1218. PubMed ID: 29688619
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study.
Chen TM; Lin KC; Yuan KS; Chang CL; Chow JM; Wu SY
Radiother Oncol; 2018 Oct; 129(1):23-29. PubMed ID: 29277447
[TBL] [Abstract][Full Text] [Related]
19. Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas.
Du L; Zhang XX; Feng LC; Qu BL; Chen J; Yang J; Liu HX; Xu SP; Xie CB; Ma L
BMC Cancer; 2017 Aug; 17(1):582. PubMed ID: 28851315
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
